Natera vs Veracyte
NTRA and VCYT side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NTRA and VCYT compare
Natera is the larger company, worth 15 times as much as Veracyte ($59.7B against $4.0B).
Natera grew revenue faster over the last twelve months (37.8% versus 17.3% for Veracyte).
Veracyte keeps more of each dollar of sales as profit, with a net margin of 20.4% compared with −7.1% at Natera.
Veracyte scores higher on the StockData Score (13 against 10 for Natera), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NTRA | VCYT |
|---|---|---|
| Size and price | ||
| Market cap | $59.7B | $4.0B |
| Share price | $414.30 | $50.01 |
| Change, 1 year | 115% | 41.2% |
| Change, 5 years | 257% | 0.10% |
| Beta (5Y) | 1.34 | 1.69 |
| Employees | 6,140 | 755 |
| StockData Score | ||
| Total score | 10 | 13 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 3 | 3 |
| Performance score | 2 | 3 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 35.7× |
| P/S | 22.1× | 7.2× (better) |
| P/B | 32.8× | 2.9× (better) |
| EV/EBITDA | – | 29.4× |
| P/FCF | 709× | 24.2× (better) |
| FCF yield | 0.14% | 4.1% (better) |
| Fair value | $124.09 | $41.65 |
| Margin of safety | −234% | −20.1% (better) |
| Growth | ||
| Revenue growth (TTM) | 37.8% (better) | 17.3% |
| Revenue growth, 5Y average | 42.6% (better) | 34.5% |
| Net income growth (TTM) | – | 335% |
| EPS growth (TTM) | – | 324% |
| Profitability | ||
| Gross margin | – | 71.7% |
| Operating margin | −10.7% | 18.8% (better) |
| Net margin | −7.1% | 20.4% (better) |
| FCF margin | 3.1% | 29.5% (better) |
| Return on equity | −12.5% | 8.8% (better) |
| Return on invested capital | −40.8% | 10.0% (better) |
| Financial health | ||
| Debt / equity | 0.04 (better) | 0.00 |
| Interest coverage | −75.9× | – |
| Current ratio | 3.00 | 9.16 (better) |
| Altman Z-score | 42.48 (better) | 25.35 |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 95.2% | 111% |
| Held by insiders | 4.0% | 1.7% |
| Insider net buying, 12 months | −$371M | −$21.0M (better) |
| Superinvestors holding | 3 | – |
| Short interest, % of float | 4.6% | 12.9% |
Go deeper
- NTRA stock overview
- NTRA income statement
- NTRA valuation and score
- VCYT stock overview
- VCYT income statement
- VCYT valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.